SWISS VENTURE CAPITAL FIRM RAISES $600 000 TO SCALE UP UNTRADITIONAL START-UP FINANCING PLATFORM

SWISS VENTURE CAPITAL FIRM RAISES $600 000 TO SCALE UP UNTRADITIONAL START-UP FINANCING PLATFORM

investiere.ch gives private investors direct access to the most promising Swiss start-up companies. Instead of building a typical VC fund, investiere.ch-s team has listened to the market and offers clients the freedom to choose from an online portfolio of carefully selected start-up businesses looking for additional funding. Small investment minimums, often averaging USD $10k attract a growing investor base. Since its launch in February 2010, the platform has gained 700 investors of which have i

Symantec Reports Fourth Quarter Fiscal 2011 Results

Symantec Reports Fourth Quarter Fiscal 2011 Results

5.2011 – .
Fourth Quarter
– GAAP Revenue of $1.67 billion
– Non-GAAP Operating Margin of 24.1 percent
– Non-GAAP Earnings Per Share of $0.38
– GAAP Deferred Revenue of $3.82 billion
– Cash Flow from Operations of $689 million
Fiscal Year 2011
– GAAP Revenue of $6.19 billion
– Non-GAAP Operating Margin of 24.8 percent
– Non-GAAP Earnings Per Share of $1.42
– Cash Flow from Operations of $1.79 billion
S

BT Group plc: Results for the fourth quarter and year to 31 March 2011

BT Group plc: Results for the fourth quarter and year to 31 March 2011

BT Group plc (BT.L) today announces its results for the fourth quarter and year to 31 March 2011.
Ian Livingston, Chief Executive, commenting on the results, said:
"We have delivered profits and free cash flow ahead of expectations for the year, while making significant investment in the business for the future. Free cash flow has nearly trebled compared with two years ago.
"We have consolidated our position as the leading provider of broadband in the UK with o

ATLAS Biolabs fulfills requirements of DIN EN ISO 13485:2003 + AC:2009 standard for development and manufacturing medical devices

ATLAS Biolabs fulfills requirements of DIN EN ISO 13485:2003 + AC:2009 standard for development and manufacturing medical devices

Berlin, May 11, 2011 – By gaining certification according to the internationally recognized quality standard DIN EN ISO 13485:2003 + AC:2009, ATLAS Biolabs GmbH has reached another milestone in its advances in the field of molecular diagnostics. DIN EN ISO 13485:2003 + AC:2009 provides the criteria for quality management in the design and manufacture of medical devices; and compliance with this standard is required in order to develop and distribute software that falls within the scope of the Eu